$1.53
0.09% today
Nasdaq, Aug 12, 04:50 pm CET
ISIN
US09077A1060
Symbol
BMEA

Biomea Fusion Inc Stock price

$1.53
-0.47 23.50% 1M
-1.96 56.16% 6M
-2.35 60.57% YTD
-4.11 72.87% 1Y
-9.97 86.70% 3Y
-17.07 91.77% 5Y
-17.07 91.77% 10Y
-17.07 91.77% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
-0.01 0.65%
ISIN
US09077A1060
Symbol
BMEA
Industry

Key metrics

Basic
Market capitalization
$91.1m
Enterprise Value
$32.7m
Net debt
positive
Cash
$58.3m
Shares outstanding
58.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
3.3
Financial Health
Equity Ratio
64.5%
Return on Equity
-268.4%
ROCE
-207.1%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-113.3m | $-110.7m
EBIT
$-115.1m | $-95.7m
Net Income
$-112.1m | $-123.1m
Free Cash Flow
$-100.4m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
22.8% | 22.3%
EBIT
22.4% | 33.6%
Net Income
19.7% | 11.1%
Free Cash Flow
10.0%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-2.8
FCF per Share
$-1.7
Short interest
18.3%
Employees
112
Rev per Employee
$0.0
Show more

Is Biomea Fusion Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

Biomea Fusion Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Biomea Fusion Inc forecast:

11x Buy
79%
3x Hold
21%

Analyst Opinions

14 Analysts have issued a Biomea Fusion Inc forecast:

Buy
79%
Hold
21%

Financial data from Biomea Fusion Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 24 24
8% 8%
-
- Research and Development Expense 91 91
26% 26%
-
-113 -113
23% 23%
-
- Depreciation and Amortization 1.84 1.84
10% 10%
-
EBIT (Operating Income) EBIT -115 -115
22% 22%
-
Net Profit -112 -112
20% 20%
-

In millions USD.

Don't miss a Thing! We will send you all news about Biomea Fusion Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Biomea Fusion Inc Stock News

Neutral
The Motley Fool
7 days ago
Biomea Fusion (BMEA) Q2 Loss Drops 44%
Neutral
GlobeNewsWire
7 days ago
SAN CARLOS, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today reported its financial results for the second quarter ended June 30, 2025, and provided a business update.
Neutral
GlobeNewsWire
19 days ago
SAN CARLOS, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced the appointment of Julianne Averill to its Board of Directors (the “Board”), effective July 22, 2025.
More Biomea Fusion Inc News

Company Profile

Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in Redwood City, CA.

Head office United States
CEO Michael Hitchcock
Employees 112
Founded 2017
Website www.biomeafusion.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today